UPDATE: MiMedx Group (MDXG) Reports Q3 EPS of $0.08, Offers Q4 Guidance
MiMedx Group (NASDAQ: MDXG) reported Q3 EPS of $0.08, versus $0.06 reported last year. Revenue for the quarter came in at $84.6 million, versus $64.43 million reported last year.
Fourth Quarter and Full Year 2017 Guidance HighlightsMiMedx provided its revenue guidance for the fourth quarter of 2017, raising both the upper and the lower ends of its revenue guidance range for full year 2017. The Company also reiterated its previously communicated guidance range for full year gross profit margins, increased its GAAP EPS guidance range as a result of the divestiture of Stability Biologics, and narrowed its guidance range for Adjusted EPS*. The Company's fourth quarter and full year 2017 guidance includes:
- Fourth quarter of 2017 revenue forecasted to be in the range of $87 to $88 million
- 2017 revenue guidance increased to the range of $320.6 to $321.6 million
- Gross profit margins for 2017 expected to be in the range of 89% to 90%
- GAAP EPS (FD) for 2017 projected to be in the range of $0.31 to $0.32
- Adjusted EPS(FD)* for 2017 projected to be in the range of $0.31 to $0.32
For earnings history and earnings-related data on MiMedx Group (MDXG) click here.